OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 02:26:21 2024-07-12 pm EDT | ||
| 16.01 EUR | -1.42% |
|
| Current month | +7.23% | ||
| 1 month | +6.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 16.01 | -1.42% |
| 24-07-11 | 16.24 | +1.31% |
| 24-07-10 | 16.03 | +2.17% |
| 24-07-09 | 15.69 | +2.55% |
| 24-07-08 | 15.3 | +4.15% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 02:26 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GK9DJX |
| ISIN | DE000GK9DJX7 |
| Date issued | 2022-08-22 |
| Strike | 317.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.4 € |
|---|---|
| Lowest since issue | 0.74 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
488.7
USD
Average target price
473.1
USD
Spread / Average Target
-3.20%
- Stock Market
- Certificates
- Certificat
